Bertelli R, Nardo B, Cavallari G, Ercolani G, Lauro A, Neri F, Tsivian M, Grazi G L, Mikus P M, Pilato E, Mikus E, Arpesella G, Pinna A D, Stefoni S, Fuga G, Faenza A
Department of Surgery, Intensive Care and Transplantation, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Transplant Proc. 2008 Jul-Aug;40(6):1867-8. doi: 10.1016/j.transproceed.2008.05.024.
We retrospectively reviewed our experience in combined liver-kidney (L-KT) and heart-kidney (H-KT) transplantations.
Between January 1997 and April 2007, we performed 25 L-KT and 5 H-KT. Patient mean age was 51+/-8 years in L-KT and 43+/-11 years in H-KT. The main cause of liver failure was chronic viral hepatitis (14 cases). Etiology of heart failure was dilated cardiomyopathy and hypertrophic cardiomyopathy (4 and 1 patients, respectively). The main causes of renal failure in L-KT were chronic glomerulonephritis (n=8) and polycystic disease (n=7). Etiology of renal failure in H-KT was interstitial nephropathy (n=2), vascular nephropathy (n=2), and chronic glomerulonephritis (n=1).
Mean follow-up was 32+/-26 months in L-KT and 24+/-17 months in H-KT. Immunosuppression was cyclosporine-based (n=4) or tacrolimus-based (n=21) in L-KT and cyclosporine-based in H-KT. Acute rejection rate was 8% for both liver and kidney in L-KT; 80% (mild) for heart and 40% for kidney in H-KT. In the L-KT group, there was no primary graft nonfunction (PGNF). Two patients experienced liver delayed graft function (DGF); 1 patient required postoperative dialysis. One-year graft and patient survivals were both 84% and overall graft and patient survival was 76%. In the H-KT group, 3 patients needed postoperative dialysis and 1 required a cardiac assistance device for 48 hours; overall graft and patient survival was 100% with good cardiac and renal functions.
Our experience confirmed that H-KT and L-KT are safe procedures, offering good long-term results.
我们回顾性分析了肝肾联合移植(L-KT)和心肾联合移植(H-KT)的经验。
1997年1月至2007年4月期间,我们实施了25例肝肾联合移植和5例心肾联合移植。肝肾联合移植患者的平均年龄为51±8岁,心肾联合移植患者的平均年龄为43±11岁。肝衰竭的主要原因是慢性病毒性肝炎(14例)。心力衰竭的病因是扩张型心肌病和肥厚型心肌病(分别为4例和1例患者)。肝肾联合移植中肾衰竭的主要原因是慢性肾小球肾炎(n = 8)和多囊肾病(n = 7)。心肾联合移植中肾衰竭的病因是间质性肾病(n = 2)、血管性肾病(n = 2)和慢性肾小球肾炎(n = 1)。
肝肾联合移植的平均随访时间为32±26个月,心肾联合移植为24±17个月。肝肾联合移植的免疫抑制方案以环孢素为主(n = 4)或他克莫司为主(n = 21),心肾联合移植以环孢素为主。肝肾联合移植中肝脏和肾脏的急性排斥率均为8%;心肾联合移植中心脏的急性排斥率为80%(轻度),肾脏为40%。在肝肾联合移植组中,没有原发性移植物无功能(PGNF)。2例患者出现肝脏移植延迟功能恢复(DGF);1例患者术后需要透析。1年移植物和患者生存率均为84%,总体移植物和患者生存率为76%。在心肾联合移植组中,3例患者术后需要透析,1例患者需要心脏辅助装置48小时;总体移植物和患者生存率为100%,心脏和肾脏功能良好。
我们的经验证实,心肾联合移植和肝肾联合移植是安全的手术,能提供良好的长期效果。